



“Biomarkers” in medical imaging are the key to detecting and treating cancer

Press release

**MEDIAN Technologies to present a poster at the
European Multidisciplinary Cancer Congress 2011 (September 23-27 in
Stockholm, Sweden)**

*Presentation of promising results regarding lesion volume used in the
assessment of response to therapy in oncology imaging*

Sophia Antipolis, Nice, France, September 20, 2011 – MEDIAN Technologies (ALMDT), the leading provider of clinical applications for quantitative management of treatment responses in oncology imaging, announces its participation to the EMCC 2011 to be held September 23-27, in Sweden. For this occasion, the company will present the results of a study on the lesion volume used in the evaluation of the treatment response of patients with advanced non-small cell lung cancer.

This presentation (poster 1147) is on schedule for the « Translational Research » session on the 24th of September 2011 from 9:30 a.m. to noon. It is entitled « Inter-reader Agreement in Response to Therapy Evaluation of Advanced Lung Cancer: Benefits of a Volume-derived Imaging Biomarker ». The abstract is available on the internet: <http://stockholm2011.ecco-org.eu/>

The study is based on follow-up CT scans of 10 patients affected by advanced non-small cell lung cancer. This study shows the impact of the use of MEDIAN LMS clinical applications on the inter-reader variability decrease for the evaluation of the treatment response according to RECIST criteria: the study shows both the advantages of the lesion volume measurement and advanced reviewing tools offered by LMS.

« We are very proud of this study’s results » underlines Arnaud Butzbach, Chief Technology Officer and Vice-President Operations at MEDIAN. *« They correspond to an additional step in demonstrating the interest of advanced imaging biomarkers in oncology, and are completely along the lines of MEDIAN Technologies project: provide pharmaceutical companies and physicians with powerful image-based data for a more reliable evaluation of the response to therapy in cancer patients ».*

MEDIAN LMS clinical applications as well as MEDIAN CTIS (Clinical Trial Imaging Services), the offer dedicated to clinical trials, will be presented on MEDIAN booth C13:13 during the whole conference.



MEDIAN

“Biomarkers” in medical imaging are the key to detecting and treating cancer

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: Based in Sophia Antipolis, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet and Arnaud Butzbach. The company has a staff of 40, over half of whom work in R&D, and has a subsidiary in the USA.

MEDIAN Technologies offers solutions and services for diagnosing and monitoring cancer patients for clinical trials market in oncology, its priority market, and the patient care market. MEDIAN collaborated with institutes at the cutting edge of medical imaging, among which the French National Institute for Computer Science and Control (INRIA), Chicago University and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL).

MEDIAN Technologies has been present in the market since 2007 through direct and indirect sales of its LMS solutions and alliances with specialist cancer centers in Europe and the USA.

For more information on MEDIAN, please visit: www.mediantechnologies.com

Contacts Presse

MEDIAN Technologies

Fredrik Brag, CEO

+33 4 92 90 65 82

fredrik.brag@mediantechnologies.com

ALIZE RP

Caroline Carmagnol

+ 33 6 64 18 99 59 // + 33 1 42 68 86 43

caroline@alizerp.com

Anne-Sophie Cosquéric

+ 33 1 42 68 86 41

Anne-sophie@alizerp.com